ARCHIVES

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

This article is from The Cancer Letter archive.

Vol. 37 No. 32 | August 12, 2011

Download PDF Visit The Full Archive

Related Articles

Obey Aide Objects To Criticism Over Earmarking New NCI Positions

August 13, 1976

Groups Have No Budgets As NCTN Begins Work March 1

February 28, 2014

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

ACS Executive Proposes Efficiency Plan, Critics Fear Erosion Of Local Influence

May 1, 1998

Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment

July 30, 2004

In Brief: Cancer Research Institute to Support AIDS Grants, With Maximum $70,000 Each; Deadline Is Oct. 1

July 15, 1983